Dezamizumab

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis[1].

Product Specifications

CAS Number

[1662664-56-3]

Product Name Alternative

GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dezamizumab.html

Purity

99.96

Solubility

10 mM in DMSO

Smiles

[Dezamizumab]

Molecular Weight

(144.18 kDa)

References & Citations

[1]Parrondo RD, et, al. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020 Dec;191 (5) :673-681.